$170.00
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like
peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes and obesity.
By targeting both GIP and GLP-1 receptors, Tirzepatide enhances insulin secretion, reduces
appetite, slows gastric emptying, and promotes significant weight loss. It has demonstrated
impressive results in clinical trials, showing improvements in blood sugar control and substantial
reductions in body weight. Tirzepatide represents a novel therapeutic option for managing
metabolic disorders and associated conditions.
nexgenresearch.com. All Rights Reserved.
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Peptide Sciences is a chemical supplier. Peptide Sciences is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Peptide Sciences is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
Reviews
There are no reviews yet.